124 patents currently held
40 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Apr 2027. from the record
Of the 40 now held by other companies, 9 were conveyed to Galvani Bioelectronics Limited in the filing they arrived in, and 31 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
4
Ending by 2030
Apr 2027
Next term end
89
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2033 · High confidence
Also notable
Ends May 2036 · High confidence
Also notable
Ends Feb 2034 · High confidence
Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
US 10,730,862
The most cited patent in this portfolio, cited by 186 later US patents, top 1% of utility patents granted in 2020 in our data. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Topical Pharmaceutical Compositions
US 11,617,724
Cited by 12 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Heterocyclic Amides as Kinase Inhibitors
US 9,556,152
Cited by 57 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2034.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 21, 2026The maintenance fee for Heterocyclic Amides as Kinase Inhibitors (US 10,292,987) comes due Nov 21, 2026. Unpaid by May 21, 2027, it lapses early.
- 2 fees due Dec 6 to 25, 2026 · next Dec 6
- 4 fees due Jan 9 to 30, 2027 · next Jan 9
- 1 fee due Mar 10, 2027The maintenance fee for Benzoimidazole Derivatives as PAD4 Inhibitors (US 10,407,407) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
- 8 fees due Apr 1 to 30, 2027 · next Apr 1
- 3 fees due May 12 to 28, 2027 · next May 12
- 1 fee due Jul 16, 2027The maintenance fee for Compounds Useful in HIV Therapy (US 11,873,310) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
- 4 fees due Sep 10 to 30, 2027 · next Sep 10
- 3 fees due Oct 2 to 30, 2027 · next Oct 2
- 3 fees due Nov 5 to 7, 2027 · next Nov 5
Recent changes
- 3 of the patents on this record were granted since Aug 19, 2026
- 2 terms have ended since Aug 19, 2026
What they patent
The 5 largest of its 89 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Heterocyclic Amides as Kinase Inhibitors | 5 in force | to Feb 2034 |
| Heterocyclic Amides Useful as Protein Modulators | 4 in force | to Mar 2038 |
| Icos Binding Proteins | 4 in force | to Nov 2036 |
| ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | 3 in force | to May 2041 |
| Compounds Useful in HIV Therapy | 3 in force | to Apr 2040 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D679,586 | Lid/Tray Package for an Inhalation Device In force · High confidence | In force | High confidence | |
| US 8,962,825 | Hydroxamates as Inhibitors of Histone Deacetylase In force · High confidence | In force | High confidence | |
| US 7,973,181 | Hydroxamic Acid Derivatives as Inhibitors of Hdac Enzymatic Activity In force · Medium confidence | In force | Medium confidence | |
| US D754,533 | Tray Package For an Inhalation Device In force · High confidence | In force | High confidence | |
| US 9,624,261 | Buffer System for Protein Purification In force · High confidence | In force | High confidence | |
| US 9,868,761 | Buffer System for Protein Purification In force · High confidence | In force | High confidence | |
| US 10,730,862 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase In force · High confidence | In force | High confidence | |
| US 9,763,965 | Aggregate Particles In force · High confidence | In force | High confidence | |
| US 9,556,152 | Heterocyclic Amides as Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,624,202 | Heterocyclic Amides as Kinase Inhibitors In force · High confidence | In force | High confidence |
Also on record, not counted in the 124: 40 patents in force now held by others · 111 patents ended · 81 applications pending · 195 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.